NEW YORK (GenomeWeb News) – Caliper Life Sciences and Monogram Biosciences are among the firms that are being removed from the Nasdaq Biotechnology Index as of the open of the market on May 18.

The Nasdaq Biotech Index performs a semi-annual re-ranking of biotech firms that it considers for either adding or dropping from the Index. In this most recent re-ranking, it added four drug firms and dropped 16 firms.

The other research products firm that was dropped from the Index was Harvard Bioscience.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.